PSNL on Nasdaq
Personalis (United States)
American medical laboratories services company based in Menlo Park.1
Price unavailable
Last updated Oct 18, 2026.
Overview
2011Founded1
Compare with Exagen Inc., Burning Rock Biotech (China) or BIODESIX INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-126.4%Operating margin4
-116.7%Net margin4
-17.7%Revenue growth, 20254
-31.1%Return on equity4
-$79.5MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue34¢$53.9M
- Research and development32¢$50.3M
- Selling, general and admin34¢$53.6M
- Interest0¢$205.0K
- Income tax0¢$21.0K
Out of $69.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cost of revenue | $53.9M | $57.8M |
| Research and development | $50.3M | $48.9M |
| Selling, general and administrative | $53.6M | $46.2M |
| Total costs and expenses | $157.7M | $152.9M |
| Loss from operations | -$88.1M | -$68.3M |
| Interest income | $7.2M | $5.5M |
| Interest expense | -$205.0K | -$24.0K |
| Other income (expense), net | -$142.0K | -$18.5M |
| Loss before income taxes | -$81.2M | -$81.3M |
| Provision for income taxes | $21.0K | $18.0K |
| Net loss | -$81.3M | -$81.3M |
| Net loss per share, basic | -$0.91 | -$1.37 |
| Net loss per share, diluted | -$0.91 | -$1.37 |
| Weighted-average shares outstanding, basic | 89.2M shares | 59.3M shares |
| Weighted-average shares outstanding, diluted | 89.2M shares | 59.3M shares |
| Revenue | $69.6M | $84.6M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $124.2M | $91.4M | |
| Short-term investments | $115.7M | $93.6M | |
| Accounts receivable, net | $16.2M | $8.1M | $17.7M |
| Inventory and other deferred costs | $6.1M | $5.9M | |
| Prepaid expenses and other current assets | $5.7M | $3.9M | |
| Total current assets | $268.0M | $203.0M | |
| Property and equipment, net | $44.8M | $48.3M | |
| Operating lease right-of-use assets | $15.1M | $16.5M | |
| Other long-term assets | $6.3M | $2.5M | |
| Total assets | $334.2M | $270.3M | |
| Accounts payable | $13.0M | $6.4M | |
| Contract liabilities | $1.6M | $3.1M | $3.3M |
| Total current liabilities | $39.6M | $31.1M | |
| Long-term operating lease liabilities | $31.9M | $34.9M | |
| Total liabilities | $73.0M | $67.3M | |
| Common stock, $0.0001 par value - 200,000,000 shares authorized; 102,475,891and 85,171,146 shares issued and outstanding, respectively | $10.0K | $9.0K | |
| Additional paid-in capital | $892.3M | $753.0M | |
| Accumulated other comprehensive income (loss) | $104.0K | -$23.0K | |
| Accumulated deficit | -$631.3M | -$550.0M | |
| Total stockholders equity | $261.2M | $203.0M | $129.4M |
| Total liabilities and stockholders equity | $334.2M | $270.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares, issued | 102.5M shares | 85.2M shares | |
| Common stock, shares, outstanding | 102.5M shares | 85.2M shares | |
| Accrued and other current liabilities | $25.1M | $21.6M | |
| Other long-term liabilities | $1.5M | $1.3M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $124.2M | $91.4M | |
| Short-term investments | $115.7M | $93.6M | |
| Accounts receivable, net | $16.2M | $8.1M | $17.7M |
| Inventory and other deferred costs | $6.1M | $5.9M | |
| Prepaid expenses and other current assets | $5.7M | $3.9M | |
| Total current assets | $268.0M | $203.0M | |
| Property and equipment, net | $44.8M | $48.3M | |
| Operating lease right-of-use assets | $15.1M | $16.5M | |
| Other long-term assets | $6.3M | $2.5M | |
| Total assets | $334.2M | $270.3M | |
| Accounts payable | $13.0M | $6.4M | |
| Contract liabilities | $1.6M | $3.1M | $3.3M |
| Total current liabilities | $39.6M | $31.1M | |
| Long-term operating lease liabilities | $31.9M | $34.9M | |
| Total liabilities | $73.0M | $67.3M | |
| Common stock, $0.0001 par value - 200,000,000 shares authorized; 102,475,891and 85,171,146 shares issued and outstanding, respectively | $10.0K | $9.0K | |
| Additional paid-in capital | $892.3M | $753.0M | |
| Accumulated other comprehensive income (loss) | $104.0K | -$23.0K | |
| Accumulated deficit | -$631.3M | -$550.0M | |
| Total stockholders equity | $261.2M | $203.0M | $129.4M |
| Total liabilities and stockholders equity | $334.2M | $270.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares, issued | 102.5M shares | 85.2M shares | |
| Common stock, shares, outstanding | 102.5M shares | 85.2M shares | |
| Accrued and other current liabilities | $25.1M | $21.6M | |
| Other long-term liabilities | $1.5M | $1.3M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$81.3M | -$81.3M |
| Stock-based compensation expense | $9.4M | $10.7M |
| Depreciation and amortization | $10.0M | $10.9M |
| Noncash operating lease cost | $1.3M | $1.4M |
| Noncash gain related to liability | $18.3M | |
| Amortization of discount on short-term investments | -$4.0M | -$2.7M |
| Other | -$302.0K | $93.0K |
| Accounts receivable | -$8.1M | $9.6M |
| Inventories and other deferred costs | -$204.0K | $4.4M |
| Prepaid expenses and other assets | -$2.2M | $1.1M |
| Accounts payable | $4.5M | -$8.9M |
| Accrued and other current liabilities | $2.3M | -$2.4M |
| Contract liabilities | -$1.5M | -$4.1M |
| Operating lease liabilities | -$3.8M | -$3.5M |
| Other long-term liabilities | -$1.2M | $1.2M |
| Net cash used in operating activities | -$74.9M | -$45.1M |
| Purchases of available-for-sale debt securities | -$210.2M | -$121.7M |
| Proceeds from maturities of available-for-sale debt securities | $192.1M | $88.0M |
| Purchases of property and equipment | -$4.5M | -$1.6M |
| Proceeds from sales of property and equipment | $242.0K | |
| Net cash used in investing activities | -$22.6M | -$35.1M |
| Proceeds from sales of common stock under ATM facility, net of commissions | $126.8M | $30.1M |
| Proceeds from exercise of Tempus Warrants | $18.4M | |
| Proceeds from sale of common stock under Tempus Investment Agreement | $17.7M | |
| Proceeds from sale of common stock under Merck Investment Agreement | $50.0M | |
| Payment of costs related to Tempus and Merck Investment Agreements | -$189.0K | -$1.2M |
| Proceeds from loans | $2.6M | |
| Repayments of loans | -$2.0M | -$1.1M |
| Proceeds from issuance of common stock under equity incentive plans | $3.1M | $770.0K |
| Net cash provided by financing activities | $130.3M | $114.7M |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $6.0K | -$22.0K |
| Net change in cash, cash equivalents and restricted cash | $32.8M | $34.4M |
| Cash paid for income taxes, net of refunds | $23.0K | $38.0K |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | $2.5M | $473.0K |
| Finance lease assets obtained in exchange for finance lease liabilities | $3.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Personalis (United States), and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
201520202025
- PresidentRichard Chen Mar 17, 2026 to now12
- Chief financial officerAaron Tachibana Jun 19, 2019 to now13
- Chief operating officerAaron Tachibana Mar 17, 2023 to now14
Board members and other officers (13)
- Chief Business OfficerClinton Musil Jun 19, 2019 to Mar 18, 202015
- Chief Scientific OfficerRichard Chen Jun 19, 2019 to now16
- Board memberKenneth J. Widder Jun 14, 2023 to now17
- Board memberOlivia Kyusuk Bloom Mar 1, 2022 to now18
- Board memberLonnie Shoff Aug 4, 2022 to now19
- Board memberWoodrow A. Myers Jr. Mar 8, 2021 to now20
- Board memberA. Blaine Bowman Jun 19, 2019 to now21
- Board memberAlan Colowick Jun 19, 2019 to May 19, 202322
- Board memberJonathan Macquitty Jun 19, 2019 to May 18, 202123
- Board memberKen Ludlum Jun 19, 2019 to May 19, 202224
- Board memberPatrick J. Balthrop Jun 19, 2019 to May 19, 202025
- Board memberPaul Ricci Jun 19, 2019 to May 19, 202026
- Board memberKarin Eastham Sep 16, 2019 to now27
Timeline
- 2011Founded Founded1
Filings
357 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 186 insider forms, 31 large holders, 59 other. The latest 20:
- Oct 6, 2026425 EDGAR
- Oct 6, 20268-K EDGAR
- Oct 2, 2026CT ORDER EDGAR
- Oct 2, 2026SC 13E3/A EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 20264 EDGAR
- Aug 31, 2026SC 13E3 EDGAR
- Aug 20, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G EDGAR
- Jul 20, 2026425 EDGAR
- Jul 20, 20268-K EDGAR
- Jul 20, 2026425 EDGAR
- Jul 20, 20268-K EDGAR
- Jul 15, 2026144 EDGAR
The 357 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 31 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Jul 29, 2026SCHEDULE 13G
- Jun 10, 2026SCHEDULE 13D/A
- May 12, 2026SCHEDULE 13G
- Apr 8, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G
- Jan 29, 2026SCHEDULE 13G/A
- Jan 8, 2026SCHEDULE 13G
- May 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Merck & Co., Inc. | 14,044,943 | $188.2M | 35.8% | No change |
| ARK Investment Management LLC | 8,271,339 | $110.8M | 0.7% | +327,227 |
| BlackRock, Inc. | 7,082,491 | $94.9M | 0.0% | +1,692,606 |
| Lightspeed Management Company, L.l.c. | 6,101,850 | $81.8M | 3.4% | −2,058,884 |
| Ameriprise Financial Inc | 6,086,315 | $81.6M | 0.0% | −1,506,492 |
| Deep Track Capital, LP | 4,000,000 | $53.6M | 0.8% | +1,000,000 |
| Aberdeen Group plc | 3,747,290 | $50.2M | 0.1% | +258,982 |
| Vanguard Capital Management LLC | 3,010,150 | $40.3M | 0.0% | +141,687 |
| Casdin Capital, LLC | 2,550,000 | $34.2M | 1.7% | +950,000 |
| Kennedy Capital Management LLC | 2,364,282 | $31.7M | 0.6% | +180,710 |
| Geode Capital Management, LLC | 1,822,445 | $24.4M | 0.0% | +524,790 |
| Bank Of America Corp /de/ | 1,820,541 | $24.4M | 0.0% | +1,709,235 |
| AIGH Capital Management LLC | 1,715,000 | $23.0M | 2.1% | −1,185,000 |
| Blue Water Life Science Advisors, LP | 1,676,300 | $22.5M | 14.1% | No change |
| Dimensional Fund Advisors LP | 1,496,983 | $20.1M | 0.0% | +430,735 |
| State Street Corp | 1,487,077 | $19.9M | 0.0% | +352,907 |
| Morgan Stanley | 1,270,946 | $17.0M | 0.0% | +1,033,631 |
| Goldman Sachs Group Inc | 931,031 | $12.5M | 0.0% | +193,899 |
| Nuveen, LLC | 753,004 | $10.1M | 0.0% | +409,484 |
| Jane Street Group, LLC | 738,241 | $9.9M | 0.0% | New |
| Vanguard Portfolio Management LLC | 659,834 | $8.8M | 0.0% | +99,295 |
| Northern Trust Corp | 632,803 | $8.5M | 0.0% | +227,003 |
| Trexquant Investment LP | 600,216 | $8.0M | 0.0% | New |
| Howland Capital Management LLC | 555,641 | $7.4M | 0.3% | +8,526 |
| State Of Michigan Retirement System | 493,798 | $6.6M | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
3 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| May 19, 2020 | Brian J. MastRepublican, House | Sale | $15,001 - $50,000 | +126.1% | Report |
| Apr 22, 2020 | Brian J. MastRepublican, House | Sale | $1,001 - $15,000 | +107.2% | Report |
| Feb 14, 2020 | Brian J. MastRepublican, House | Buy | $15,001 - $50,000 | −75.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitewww.personalis.com1
- WikidataQ30260685
- SEC EDGARCIK 1527753
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARRichard Chen, President
- 13
- 14
- 15
- 16
- 17SEC EDGARKenneth J. Widder, Board member
- 18SEC EDGAROlivia Kyusuk Bloom, Board member
- 19SEC EDGARLonnie Shoff, Board member
- 20SEC EDGARWoodrow A. Myers Jr., Board member
- 21SEC EDGARA. Blaine Bowman, Board member
- 22SEC EDGARAlan Colowick, Board member
- 23SEC EDGARJonathan Macquitty, Board member
- 24SEC EDGARKen Ludlum, Board member
- 25SEC EDGARPatrick J. Balthrop, Board member
- 26SEC EDGARPaul Ricci, Board member
- 27SEC EDGARKarin Eastham, Board member